K2 VBI Equity Trust, LLC acquires VBI Vaccines Inc. (2025)

Deal facts

Buyer: K2 VBI Equity Trust, LLC
Target: VBI Vaccines Inc.
Deal value: Not disclosed
Announced: 3 January 2025
Status: Completed
Sector: Healthcare
Country: Canada
Consideration: shares

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

3 Jan 2025CompletedClosed
K2 VBI Equity Trust, LLC completes acquisition of VBI Vaccines Inc.
Item 2.01. Completion of Acquisition or Disposition of Assets As previously disclosed, on July 30, 2024, VBI Vaccines Inc. (the “ Company ”) and its subsidiaries commenced voluntary restructuring under the jurisdiction of the Ontario Superior Court of Justice (Commercial List) (the “ Court ”) pursuant to the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the “ CCAA ”). On
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of VBI Vaccines Inc by K2 VBI Equity Trust, LLC. This transaction, announced on 3 January 2025, marks a definitive shift from public markets to private ownership for a Canadian healthcare firm. The deal structure is a classic going-private move where the consideration consists entirely of shares in the acquiring entity. There is no cash component disclosed, which places the entire value proposition on the future equity performance of the new private vehicle. This mechanism removes the quarterly earnings pressure that often constrains long-term biotech strategy, yet it also transfers market liquidity risk directly to the selling shareholders.

The cross-border nature of this deal, moving a Canadian target into a US private trust, introduces specific regulatory and commercial mechanics that the SME founder must respect. While the deal is already marked as completed, the path to this finish line almost certainly required scrutiny under Canadian competition laws and potentially US anti-trust thresholds given the healthcare sector sensitivity. For founders in similar positions, the reliance on share-based consideration in a going-private scenario means the exit is not truly final until the new shares are liquid or listed. This structure often includes change-of-control covenants that lock up capital for extended periods, a reality that differs sharply from a cash buyout.

We think this move highlights a growing trend where specialised trusts are stepping in to provide an exit route when public valuations fail to reflect underlying scientific progress. The absence of a disclosed monetary value in the announcement underscores the complexity of valuing pre-revenue or early-stage biotech assets in a private setting. For the SME founder watching this space, the lesson is about understanding the liquidity profile of your exit. A share-only deal in a private trust offers strategic freedom but demands a clear plan for how and when you will realise value from those new holdings.

Your immediate action this week should be to audit the liquidity terms of any current or potential exit proposal. If a buyer offers only equity in a private vehicle, demand a written schedule outlining the specific conditions and timelines required to convert those shares into cash or a public listing. Do not sign a deal based on the promise of future value without a defined mechanism for exit from the private structure itself.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from K2 VBI Equity Trust, LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history